TG Therapeutics (TGTX) Stock Price, News & Analysis

Company Overview

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe. The company was previously associated with Ukoniq (umbralisib), which it voluntarily withdrew from the U.S. market in 2022.

Key Stats

• Today's Range: $62.00 to $68.03
• 50-Day Range: $52.19 to $64.26
• 52-Week Range: $26.76 to $68.03
• Volume: 5.79 million shs
• Average Volume: 1.86 million shs
• Market Capitalization: $9.84 billion
• P/E Ratio: 97.37
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Moderate Buy

TG Therapeutics Stock Analysis - MarketRank™

TG Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 502nd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for TG Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

TG Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 188.04%

Earnings Growth

Earnings for TG Therapeutics are expected to grow by 188.04% in the coming year, from $0.92 to $2.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TG Therapeutics is 97.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.18.

Price to Earnings Ratio vs. Sector

The P/E ratio of TG Therapeutics is 97.37, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.77.

Price to Earnings Growth Ratio

TG Therapeutics has a PEG Ratio of 2.68. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

TG Therapeutics has a P/B Ratio of 15.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.62% of the float of TG Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TG Therapeutics has a short interest ratio ("days to cover") of 18.89, which indicates bearish sentiment.

Change versus previous month

Short interest in TG Therapeutics has recently decreased by 2.78%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TG Therapeutics does not currently pay a dividend.

Dividend Growth

TG Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.38

News Sentiment

TG Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for TG Therapeutics this week, compared to 5 articles on an average week.

Search Interest

15 people have searched for TGTX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $274,800.00 in company stock.

Percentage Held by Insiders

8.87% of the stock of TG Therapeutics is held by insiders.

Percentage Held by Institutions

58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/09/2026
• Today: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TGTX
• Previous Symbol: OTCMKTS:TGTX
• CIK: 1001316
• Web: www.tgtherapeutics.com
• Phone: (212) 554-4484
• Fax: 212-554-4531
• Employees: 399
• Year Founded: 1993

Price Target and Rating

• Average Price Target for TG Therapeutics: $63.00
• High Price Target: $86.00
• Low Price Target: $20.00
• Potential Upside/Downside: -2.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.74
• Trailing P/E Ratio: 97.37
• Forward P/E Ratio: 24.25
• P/E Growth: 2.68
• Net Income: $447.18 million
• Net Margins: 11.81%
• Pretax Margin: 16.66%
• Return on Equity: 18.52%
• Return on Assets: 8.03%

Debt

• Debt-to-Equity Ratio: 1.23
• Current Ratio: 4.27
• Quick Ratio: 3.72

Sales & Book Value

• Annual Sales: $616.29 million
• Price / Sales: 15.96
• Cash Flow: $2.84 per share
• Price / Cash Flow: 22.62
• Book Value: $4.08 per share
• Price / Book: 15.75

Miscellaneous

• Outstanding Shares: 153,070,000
• Free Float: 139,492,000
• Market Cap: $9.84 billion
• Optionable: Optionable
• Beta: 1.89